Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price increased by investment analysts at Nomura from $148.00 to $156.00 in a research note issued on Thursday, March 15th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Nomura’s target price would indicate a potential upside of 42.80% from the company’s current price.
Other research analysts also recently issued reports about the stock. Stifel Nicolaus restated a “buy” rating and set a $151.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, February 9th. Deutsche Bank set a $161.00 price objective on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 9th. Citigroup lowered their price objective on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research report on Friday, February 9th. Credit Suisse Group reiterated a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, December 12th. Finally, Leerink Swann reiterated a “buy” rating and set a $169.00 price target on shares of Alexion Pharmaceuticals in a report on Wednesday, December 6th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and twenty have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $155.55.
Shares of NASDAQ:ALXN opened at $109.24 on Thursday. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a market cap of $24,305.99, a PE ratio of 21.17, a PEG ratio of 1.01 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter in the previous year, the company posted $1.26 earnings per share. The business’s revenue was up 9.5% on a year-over-year basis. sell-side analysts predict that Alexion Pharmaceuticals will post 6.12 earnings per share for the current fiscal year.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 13,245 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $1,540,525.95. Following the completion of the sale, the chief executive officer now owns 131,425 shares in the company, valued at approximately $15,286,041.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP John B. Moriarty sold 3,363 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $115.70, for a total transaction of $389,099.10. Following the completion of the sale, the executive vice president now owns 71,400 shares of the company’s stock, valued at approximately $8,260,980. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,700 shares of company stock valued at $3,345,708. Company insiders own 4.35% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Delpha Capital Management LLC bought a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at approximately $102,000. Valeo Financial Advisors LLC bought a new position in shares of Alexion Pharmaceuticals during the 3rd quarter valued at approximately $147,000. CNB Bank bought a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at approximately $150,000. Beacon Investment Advisory Services Inc. bought a new position in shares of Alexion Pharmaceuticals during the 3rd quarter valued at approximately $201,000. Finally, Invictus RG bought a new position in shares of Alexion Pharmaceuticals during the 3rd quarter valued at approximately $202,000. 95.36% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Price Target Increased to $156.00 by Analysts at Nomura” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/alexion-pharmaceuticals-alxn-given-new-156-00-price-target-at-nomura.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.